BETHLEHEM, Pa., March 3, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche announced today that the U.S. Food and Drug Administration ("FDA") has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays developed to be used exclusively as part of OraSure's Intercept ® Oral Fluid Drug Testing System. The cleared oral fluid assays include Phencyclidine (PCP), Cocaine, Opiates and Methamphetamine.
The oral fluid assays use Roche's KIMS (kinetic interaction of micro-particles in solution) technology and were jointly developed under an agreement previously signed by the parties. These assays are designed to run on various clinical chemistry automated analyzers, which are intended to allow oral fluid samples to be processed with the same efficiency as current fully automated urine-based drug tests.
"We are very pleased to announce this significant milestone in our joint effort with Roche to develop and market these important drugs of abuse assays," said Douglas A. Michels, President and CEO of OraSure Technologies. "The combination of Roche's industry leadership in lab instrumentation and reagent chemistry and our leadership in oral fluid technology and sample collection devices has enabled us to bring to market a breakthrough system that will have an immediate and positive impact on laboratory efficiency for drugs of abuse testing.""The approval of this first set of fully automated oral fluid drugs of abuse assays demonstrates the strengths and experience of both companies," said Frank G. Sieben, SVP and Life Cycle Leader of Roche Professional Diagnostics. "Specifically the technologies and expertise of our collective research and development teams will enable us to provide novel high throughput oral fluid drug testing solutions." The Companies anticipate the first four assays to be available for sale later this year. Several additional assays are also in development and are currently in varying stages of submission with the FDA.